Xilonix, a novel anti-cancer agent, is being developed via a ground-breaking regulatory path that XBiotech established in collaboration with the scientific advisory committee of the European Medicines Agency
The focus of the collaboration, originally signed in 2014, is the development and validation of HiFiBiO’s proprietary, high throughput antibody discovery platform for deep mining of immune repertoires.
Unituxin is administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin. Neuroblastoma is the most common extracranial solid cancer in childhood and the most common
Under the terms of the agreement, AVEO will receive an upfront payment of $15 million and will be eligible to receive reimbursement, clinical, sales and regulatory-based milestone payments
Under the agreement, New WuXi Life will acquire WuXi PharmaTech for cash consideration equal to $5.75 per ordinary share and $46 per American depositary share (ADS). Each ADS
The phase 3 trial is designed as a randomized, double-blind, placebo-controlled study of about 400 HLA-A2 positive subjects, which will be conducted at about 120 sites in the
This study evaluated the safety and technical feasibility of a single treatment of vonapanitase via a drug-delivery catheter on atherosclerotic human arteries. The data indicate that catheter-based treatment
In addition to the high efficacy, the results showed an excellent tolerability and safety profile with low risk of hypoglycemia or other side effects (such as gastrointestinal discomfort)
The availability of Karbinal ER provides physicians with a new, effective and easy to use treatment option for children with seasonal and perennial allergic rhinitis that need symptomatic
G1T28 is an intravenous (IV) therapy being studied as a bone marrow and immune system chemoprotectant in patients with SCLC who are receiving chemotherapy. The two Phase 1b/2a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.